Text Size
36 studies found for:    PCI-32765

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765
Condition: Healthy Volunteers
Interventions: Drug: Sequence 1: PCI-32765;   Drug: Sequence 2: PCI-32765;   Drug: Sequence 3: PCI-32765;   Drug: Sequence 4: PCI-32765
2 Recruiting PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Conditions: Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Other: Correlative laboratory samples;   Other: quality of life assessment
3 Recruiting A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
Condition: Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
4 Completed A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants
Condition: Healthy Participants
Intervention: Drug: Ibrutinib
5 Not yet recruiting A Long-term Extension Study of PCI-32765 (Ibrutinib)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B-cell Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
6 Recruiting Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
Condition: Leukemia
Interventions: Other: Heavy Water (2H2O);   Drug: PCI-32765
7 Completed A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants
Condition: Healthy Participants
Interventions: Drug: PCI-32765;   Drug: Rifampin
8 Not yet recruiting A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
9 Recruiting A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
Condition: Hepatic Impairment
Intervention: Drug: PCI-32765
10 Recruiting A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms
Condition: Recurrent Mature B-cell Neoplasms
Intervention: Drug: PCI-32765
11 Recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: BTK inhibitor PCI-32765;   Biological: rituximab;   Drug: bendamustine hydrochloride;   Other: pharmacogenomic studies;   Other: pharmacological study;   Other: laboratory biomarker analysis
12 Recruiting Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: PCI-32765
13 Completed Safety of PCI-32765 in Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
14 Recruiting A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Conditions: Chronic Lymphocytic Leukemia With 17p Deletion;   Small Lymphocytic Lymphoma With 17p Deletion
Intervention: Drug: PCI-32765
15 Completed A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants
Condition: Healthy
Interventions: Drug: Ibrutinib;   Drug: Ketoconazole
16 Recruiting Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma
Conditions: Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma
Interventions: Drug: ibrutinib;   Other: laboratory biomarker analysis
17 Recruiting A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
Condition: CD20-positive B-cell Non-Hodgkin Lymphoma
Interventions: Drug: Part 1, Cohort 1;   Drug: Part 1, Cohort 2;   Drug: Part 1, Cohort 3;   Drug: Part 2, Cohort 1;   Drug: Part 2, Cohort 2
18 Active, not recruiting Safety and Efficacy of PCI-32765 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Condition: Mantle Cell Lymphoma
Intervention: Drug: PCI-32765
19 Not yet recruiting Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
Conditions: Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
Interventions: Drug: lenalidomide;   Drug: ibrutinib;   Biological: rituximab;   Other: pharmacological study;   Other: laboratory biomarker analysis
20 Active, not recruiting Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients
Condition: Leukemia
Interventions: Drug: Rituximab;   Drug: PCI-32765
To Top

Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results
† Indicates status has not been verified in more than two years